Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- No Major Safety Concerns for COVID-19 Vaccines in Japan: Experts
October 11, 2022
- Japan Cabinet OKs Bill to Amend Infectious Disease Act, Other Laws
October 11, 2022
- AstraZeneca’s Evusheld Added to Updated MHLW COVID Guide
October 11, 2022
- Comirnaty Bags Special Approval in Japan for Kids Aged 6 Months to 4 Years
October 6, 2022
- Pfizer’s BA.4/5-Adapted Comirnaty Grabs Special Approval in Japan
October 6, 2022
- LDP Health Panel Chief Vows All-Round Support for Japan Drug Makers
October 6, 2022
- JMA Deputy Chief Shigematsu Joins Chuikyo Succeeding Kimori
October 6, 2022
- Chuikyo Kicks Off Debate on FY2023 Off-Year Drug Price Revision
October 6, 2022
- Japan Panel OKs Inclusion of Silgard 9 into National Immunization Program
October 5, 2022
- Japan Convenes Diet Session; Bill Submission Planned to Amend Infectious Disease Act, Medical Care Act
October 4, 2022
- Govt Plans to Designate Key Resources Before End of Year: Minister
October 4, 2022
- MHLW Panel Proposes Lifting Bans on Cannabis-Derived Drugs, Introducing Distribution Control
October 3, 2022
- Japan Ends Supply of AstraZeneca’s COVID Jab, 13.5 Million Doses Discarded
October 3, 2022
- PMDA Will “Appropriately Review” Lecanemab If Filed: Minister
October 3, 2022
- Wholesalers Question Inflexibility in Official Pricing, Sees Limit to Addressing Rising Costs
September 30, 2022
- Crecon President Sounds Alarm over Hollowing-Out of Domestic Manufacturing
September 30, 2022
- Trade Group Calls for New Pricing Model for Regenerative Medicine Products
September 30, 2022
- Japan Set to Distribute Pfizer’s COVID Jab for 6 Months to 4 Years of Age from Late October
September 30, 2022
- 2% Buffer Zone Has Multiple Functions, Should Not Be Reduced: JPWA
September 30, 2022
- Japan Panel to Discuss Comirnaty for Kids Aged 6 Months to 4 Years on Oct. 5
September 29, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…